Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Establishment Labs to Participate in 41st Annual J.P. Morgan Healthcare Conference

BusinessWire_EN 
0 0 28.12.22
Establishment Labs to Participate in 41st Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20221110005145/en/1631594/5/ESTA_logo_color.jpg
 

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 7:30 a.m. Pacific Time.

A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, over 2.5 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Mia Femtech™, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221228005077/en/

Establishment Labs Holdings Inc Stock

€41.00
-0.490%
The price for the Establishment Labs Holdings Inc stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.490%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Establishment Labs Holdings Inc.
As a result the target price of 52 € shows a positive potential of 26.83% compared to the current price of 41.0 € for Establishment Labs Holdings Inc.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!